The goals of this study are to evaluate the safety and tolerability of multiple ascending doses of PF-04455242 administered orally to healthy adult subjects. In addition, the plasma and urine pharmacokinetics of multiple ascending doses of PF 04455242 administered orally to healthy adult subjects will be evaluated. Finally, the effect of multiple-doses of PF-04455242 on serum prolactin concentration will be explored.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Enrollment
36
3, 6, and 23 mg capsules administered orally Q6 hours for 7 days of dosing.
Placebo administered orally Q6 hours for 7 days of dosing.
Pfizer Investigational Site
Singapore, Singapore
Safety and tolerability of multiple ascending doses of PF 04455242 administered orally to healthy adult subjects.
Time frame: 10 days
Plasma and urine pharmacokinetics of multiple ascending doses of PF 04455242 administered orally to healthy adult subjects.
Time frame: 10 days
Effect of multiple-doses of PF 04455242 on serum prolactin concentration.
Time frame: 10 days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.